Remedy Pharmaceuticals Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur

Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece t

With analysts watching Biogen Inc. closely for signs of a major deal, the US biotech has instead taken a little step down the merger and acquisition pathway by inking an option agreement to acquire

Biogen Inc. 's Spinraza (nusinersen) is the company's big near-term growth driver, so the fact that sales of the drug for the life-threatening neurodegenerative condition spinal muscular atrophy (SM